002693 *ST双成
交易中 01-15 10:36:24
资讯
新帖
简况
异动快报:*ST双成(002693)1月8日10点34分触及涨停板
证券之星 · 01-08
异动快报:*ST双成(002693)1月8日10点34分触及涨停板
*ST双成(002693)披露控股子公司通过高新技术企业认定,1月6日股价上涨1.54%
证券之星 · 01-06
*ST双成(002693)披露控股子公司通过高新技术企业认定,1月6日股价上涨1.54%
*ST双成:硼替佐米ANDA获FDA上市许可
证券之星 · 2025-12-25
*ST双成:硼替佐米ANDA获FDA上市许可
异动快报:*ST双成(002693)12月22日9点56分触及涨停板
证券之星 · 2025-12-22
异动快报:*ST双成(002693)12月22日9点56分触及涨停板
异动快报:*ST双成(002693)12月19日9点37分触及涨停板
证券之星 · 2025-12-19
异动快报:*ST双成(002693)12月19日9点37分触及涨停板
*ST双成(002693.SZ):注射用硼替佐米ANDA获得美国FDA上市许可
智通财经 · 2025-12-18
*ST双成(002693.SZ):注射用硼替佐米ANDA获得美国FDA上市许可
*ST双成:主营业务涵盖药品研发生产销售
证券之星 · 2025-12-09
*ST双成:主营业务涵盖药品研发生产销售
*ST双成:公司是否触及退市风险警示需经2025年度审计判断
证券之星 · 2025-12-09
*ST双成:公司是否触及退市风险警示需经2025年度审计判断
*ST双成(002693)公司公告终止实施2025年限制性股票与股票期权激励计划,12月05日股价下跌1.84%
证券之星 · 2025-12-05
*ST双成(002693)公司公告终止实施2025年限制性股票与股票期权激励计划,12月05日股价下跌1.84%
*ST双成:销售模式为招商与市场推广结合
证券之星 · 2025-11-26
*ST双成:销售模式为招商与市场推广结合
异动快报:*ST双成(002693)11月19日13点3分触及跌停板
证券之星 · 2025-11-19
异动快报:*ST双成(002693)11月19日13点3分触及跌停板
*ST双成(002693)披露终止实施2025年限制性股票与股票期权激励计划,11月18日股价上涨4.96%
证券之星 · 2025-11-18
*ST双成(002693)披露终止实施2025年限制性股票与股票期权激励计划,11月18日股价上涨4.96%
异动快报:*ST双成(002693)11月18日9点35分触及涨停板
证券之星 · 2025-11-18
异动快报:*ST双成(002693)11月18日9点35分触及涨停板
*ST双成:企业所得税已享受15%税率
证券之星 · 2025-11-07
*ST双成:企业所得税已享受15%税率
*ST双成(002693)9月30日股东户数4.42万户,较上期减少19.43%
证券之星 · 2025-10-30
*ST双成(002693)9月30日股东户数4.42万户,较上期减少19.43%
*ST双成:公司没有该专利
证券之星 · 2025-10-30
*ST双成:公司没有该专利
*ST双成:不存在提前泄露3季度业绩的情况
证券之星 · 2025-10-30
*ST双成:不存在提前泄露3季度业绩的情况
股市必读:*ST双成(002693)10月29日董秘有最新回复
证券之星 · 2025-10-30
股市必读:*ST双成(002693)10月29日董秘有最新回复
图解*ST双成三季报:第三季度单季净利润同比增长176.31%
证券之星 · 2025-10-30
图解*ST双成三季报:第三季度单季净利润同比增长176.31%
股市必读:*ST双成(002693)10月28日董秘有最新回复
证券之星 · 2025-10-29
股市必读:*ST双成(002693)10月28日董秘有最新回复
加载更多
公司概况
公司名称:
海南双成药业股份有限公司
所属行业:
医药制造业
上市日期:
2012-08-08
主营业务:
海南双成药业股份有限公司的主营业务是药品注射剂、固体制剂、原料药的研发、生产、销售。公司的主要产品是注射用生长抑素、注射用比伐芦定、依替巴肽注射液、醋酸奥曲肽注射液、注射用紫杉醇(白蛋白结合型)。公司曾荣获国家知识产权示范企业、优势企业奖励。
发行价格:
20.00
{"stockData":{"symbol":"002693","market":"SZ","secType":"STK","nameCN":"*ST双成","latestPrice":7.21,"timestamp":1768444584000,"preClose":7.45,"halted":0,"volume":5281325,"delay":0,"changeRate":-0.0322,"floatShares":411000000,"shares":415000000,"eps":-0.1037,"marketStatus":"交易中","change":-0.24,"latestTime":"01-15 10:36:24","open":7.45,"high":7.45,"low":7.17,"amount":38614200,"amplitude":0.0376,"askPrice":7.21,"askSize":348,"bidPrice":7.2,"bidSize":1983,"shortable":0,"etf":0,"ttmEps":-0.1037,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1768447800000},"marketStatusCode":2,"adr":0,"adjPreClose":7.45,"symbolType":"stock","openAndCloseTimeList":[[1768440600000,1768447800000],[1768453200000,1768460400000]],"highLimit":7.82,"lowLimit":7.08,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":414689750,"isCdr":false,"pbRate":7.9,"roa":"--","roe":"--","epsLYR":-0.19,"committee":0.523541,"marketValue":2990000000,"turnoverRate":0.0129,"status":1,"floatMarketCap":2963000000},"requestUrl":"/m/hq/s/002693","defaultTab":"news","newsList":[{"id":"2601367023","title":"异动快报:*ST双成(002693)1月8日10点34分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601367023?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:35","pubTimestamp":1767839722,"startTime":"0","endTime":"0","summary":"证券之星1月8日盘中消息,10点34分*ST双成触及涨停板。其所属行业化学制药目前上涨。领涨股为必贝特。该股为肝炎概念,阿尔茨海默病,化学原料药概念热股,当日肝炎概念概念上涨1.24%,阿尔茨海默病概念上涨1.19%,化学原料药概念上涨0.89%。1月7日的资金流向数据方面,主力资金净流入337.6万元,占总成交额8.08%,游资资金净流出175.47万元,占总成交额4.2%,散户资金净流出162.13万元,占总成交额3.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800011319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2601132028","title":"*ST双成(002693)披露控股子公司通过高新技术企业认定,1月6日股价上涨1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601132028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601132028?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:30","pubTimestamp":1767709837,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘,*ST双成报收于7.26元,较前一交易日上涨1.54%,最新总市值为30.11亿元。该股当日开盘7.15元,最高7.35元,最低7.14元,成交额达5648.32万元,换手率为1.9%。公司近日发布公告称,其控股子公司宁波双成药业有限公司被认定为宁波市2025年度第一批高新技术企业,证书编号GR202533101446,发证日期2025年12月8日,有效期三年。本次为首次认定,根据相关规定,宁波双成在三年内将按15%的税率缴纳企业所得税。该事项不会对公司当期经营业绩产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2594234050","title":"*ST双成:硼替佐米ANDA获FDA上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2594234050","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594234050?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:51","pubTimestamp":1766667100,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成(002693)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司的硼替佐米美国订单是否落地?FDA相关进展如何?*ST双成回复:尊敬的投资者您好,公司产品注射用硼替佐米ANDA已获得美国FDA上市许可,详见公司于2025年12月19日披露的公告。感谢你的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2593717202","title":"异动快报:*ST双成(002693)12月22日9点56分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2593717202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593717202?lang=zh_cn&edition=full","pubTime":"2025-12-22 10:01","pubTimestamp":1766368876,"startTime":"0","endTime":"0","summary":"证券之星12月22日盘中消息,9点56分*ST双成触及涨停板。其所属行业化学制药目前上涨。领涨股为康芝药业。该股为海南概念,半导体,化学原料药概念热股,当日海南概念概念上涨8.26%,半导体概念上涨1.78%,化学原料药概念上涨0.06%。12月19日的资金流向数据方面,主力资金净流入1292.69万元,占总成交额26.02%,游资资金净流出183.2万元,占总成交额3.69%,散户资金净流出1109.49万元,占总成交额22.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200003362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2592361731","title":"异动快报:*ST双成(002693)12月19日9点37分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2592361731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592361731?lang=zh_cn&edition=full","pubTime":"2025-12-19 09:41","pubTimestamp":1766108469,"startTime":"0","endTime":"0","summary":"证券之星12月19日盘中消息,9点37分*ST双成触及涨停板。其所属行业化学制药目前上涨。领涨股为河化股份。该股为海南概念,肝炎概念,化学原料药概念热股,当日海南概念概念上涨0.57%,肝炎概念概念上涨0.27%,化学原料药概念上涨0.21%。12月18日的资金流向数据方面,主力资金净流出430.47万元,占总成交额13.42%,游资资金净流入299.45万元,占总成交额9.33%,散户资金净流入131.02万元,占总成交额4.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900006464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2592097519","title":"*ST双成(002693.SZ):注射用硼替佐米ANDA获得美国FDA上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2592097519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592097519?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:24","pubTimestamp":1766046271,"startTime":"0","endTime":"0","summary":"智通财经APP讯,*ST双成(002693.SZ)公告,公司近日收到美国食品和药品监督管理局(简称“FDA”)的通知,公司向美国FDA提交的注射用硼替佐米简略新药申请(简称“ANDA”)已获得美国FDA的批准。美国FDA对公司递交的注射用硼替佐米ANDA申报资料进行了全面技术审评,认定公司的产品与原研药品生物等效和疗效等效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"*ST双成(002693.SZ):注射用硼替佐米ANDA获得美国FDA上市许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2590134629","title":"*ST双成:主营业务涵盖药品研发生产销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590134629?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:51","pubTimestamp":1765284693,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成(002693)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司是否考虑过向不同领域开展业务?*ST双成回复:尊敬的投资者您好,公司所属行业为医药制造业,公司主营业务涵盖药品注射剂、固体制剂、原料药的研发、生产、销售等,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2590346406","title":"*ST双成:公司是否触及退市风险警示需经2025年度审计判断","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590346406?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:51","pubTimestamp":1765284686,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成12月08日在投资者关系平台上答复投资者关心的问题。投资者提问:若*ST双成2025年全年净利润为正但营收不足3亿,能否成功保壳并撤销退市风险警示(摘帽)?*ST双成回复:尊敬的投资者您好。公司是否触及上述条款需经2025年度会计师审计的年度报告进行判断,公司将严格按照股票上市规则的相关规定,认真履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900037426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2589093818","title":"*ST双成(002693)公司公告终止实施2025年限制性股票与股票期权激励计划,12月05日股价下跌1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589093818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589093818?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:23","pubTimestamp":1764944609,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘,*ST双成报收于6.93元,较前一交易日下跌1.84%,最新总市值为28.74亿元。近日,海南双成药业股份有限公司召开2025年第三次临时股东会,审议通过了《关于终止实施2025年限制性股票与股票期权激励计划的议案》。公告显示,出席会议的股东共382人,代表股份218,948,475股,占公司总股份的52.7981%。表决结果显示,同意股份数占出席股东会有效表决权股份总数的95.9021%,反对占3.9976%,弃权占0.1004%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2586347252","title":"*ST双成:销售模式为招商与市场推广结合","url":"https://stock-news.laohu8.com/highlight/detail?id=2586347252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586347252?lang=zh_cn&edition=full","pubTime":"2025-11-26 20:48","pubTimestamp":1764161310,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成11月25日在投资者关系平台上答复投资者关心的问题。*ST双成回复:尊敬的投资者您好,公司销售模式主要是招商和市场推广相结合的模式,公司在各地区派驻商务经理,产品以地区或医院为单位进行招商,由专业市场推广公司负责市场调研,学术培训,产品宣传,临床指导,各地商业公司负责药品配送,公司销售人员包括公司商务经理及销售内勤等人员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600035628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2584992387","title":"异动快报:*ST双成(002693)11月19日13点3分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2584992387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584992387?lang=zh_cn&edition=full","pubTime":"2025-11-19 13:05","pubTimestamp":1763528727,"startTime":"0","endTime":"0","summary":"证券之星11月19日盘中消息,13点3分*ST双成(002693)触及跌停板。目前价格8.05,下跌4.85%。其所属行业化学制药目前下跌。领涨股为山河药辅。该股为半导体,阿尔茨海默病,化学原料药概念热股。11月18日的资金流向数据方面,主力资金净流入2858.27万元,占总成交额12.55%,游资资金净流出1253.06万元,占总成交额5.5%,散户资金净流出1605.21万元,占总成交额7.05%。近5日资金流向一览见下表:*ST双成主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900017972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002693"],"gpt_icon":0},{"id":"2584953437","title":"*ST双成(002693)披露终止实施2025年限制性股票与股票期权激励计划,11月18日股价上涨4.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584953437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584953437?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:13","pubTimestamp":1763475201,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘,*ST双成报收于8.46元,较前一交易日上涨4.96%,最新总市值为35.08亿元。近日,海南双成药业股份有限公司发布公告称,公司于2025年11月18日召开第五届董事会第二十四次会议,审议通过了关于终止实施2025年限制性股票与股票期权激励计划的议案。截至公告日,激励计划尚未实际授予,不影响公司股权结构和财务状况。公司承诺自公告之日起3个月内不再审议股权激励计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2584609085","title":"异动快报:*ST双成(002693)11月18日9点35分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2584609085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584609085?lang=zh_cn&edition=full","pubTime":"2025-11-18 09:40","pubTimestamp":1763430049,"startTime":"0","endTime":"0","summary":"证券之星11月18日盘中消息,9点35分*ST双成触及涨停板。目前价格8.35,上涨3.6%。其所属行业化学制药目前上涨。领涨股为海南海药。该股为海南概念,阿尔茨海默病,化学原料药概念热股,当日海南概念概念上涨1.83%,阿尔茨海默病概念上涨0.52%,化学原料药概念上涨0.32%。11月17日的资金流向数据方面,主力资金净流出1049.13万元,占总成交额16.97%,游资资金净流入282.78万元,占总成交额4.58%,散户资金净流入766.34万元,占总成交额12.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800008027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2581888486","title":"*ST双成:企业所得税已享受15%税率","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581888486?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:51","pubTimestamp":1762519915,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成11月06日在投资者关系平台上答复投资者关心的问题。*ST双成回复:尊敬的投资者您好,感谢关注,关于海南自由贸易港政策,其中“对注册在海南自贸港并实质性运营的鼓励类产业企业,减按15%的税率征收企业所得税”,我司是高新技术企业,企业所得税已享受15%的税率。公司一直密切关注并深入研究海南自由贸易港的相关政策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700036575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2579136911","title":"*ST双成(002693)9月30日股东户数4.42万户,较上期减少19.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579136911","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579136911?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:40","pubTimestamp":1761817207,"startTime":"0","endTime":"0","summary":"证券之星消息,近日*ST双成披露,截至2025年9月30日公司股东户数为4.42万户,较6月30日减少1.07万户,减幅为19.43%。户均持股数量由上期的7565.0股增加至9389.0股,户均持股市值为7.23万元。在化学制药行业个股中,*ST双成股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.43万户。从股价来看,2025年6月30日至2025年9月30日,*ST双成区间涨幅为4.62%,在此期间股东户数减少1.07万户,减幅为19.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002693"],"gpt_icon":0},{"id":"2579319745","title":"*ST双成:公司没有该专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579319745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579319745?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:00","pubTimestamp":1761814834,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成(002693)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问:专利名称:一种无菌兰瑞肽原料药的制备方法,是否为贵公司专利?*ST双成回复:尊敬的投资者您好,感谢您的关注。公司没有该专利。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000030959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002693"],"gpt_icon":0},{"id":"2579975201","title":"*ST双成:不存在提前泄露3季度业绩的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2579975201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579975201?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:57","pubTimestamp":1761814633,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成(002693)10月30日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司3季度业绩是否已经泄露?二级市场如此剧烈波动*ST双成回复:尊敬的投资者您好,二级市场股价波动受多重因素共同影响,包括宏观经济环境、资本市场整体走势、行业周期特征、公司基本面以及市场情绪等。公司严格执行《信息披露管理办法》及《内幕信息知情人登记、管理和保密制度》等相关规定,始终高度重视信息保密工作,不存在提前泄露3季度业绩的情况。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000030863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0},{"id":"2579132670","title":"股市必读:*ST双成(002693)10月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579132670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579132670?lang=zh_cn&edition=full","pubTime":"2025-10-30 05:31","pubTimestamp":1761773475,"startTime":"0","endTime":"0","summary":"截至2025年10月29日收盘,*ST双成报收于7.77元,下跌0.51%,换手率3.55%,成交量14.6万手,成交额1.13亿元。董秘最新回复投资者: 今年的财务指标已经符合退市标准,为何还要搞股权激励董秘: 尊敬的投资者您好,感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000004154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002693"],"gpt_icon":0},{"id":"2579109187","title":"图解*ST双成三季报:第三季度单季净利润同比增长176.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579109187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579109187?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:01","pubTimestamp":1761764486,"startTime":"0","endTime":"0","summary":"证券之星消息,*ST双成2025年三季报显示,前三季度公司主营收入1.69亿元,同比上升33.04%;归母净利润-252.35万元,同比上升93.33%;扣非净利润-586.62万元,同比上升85.31%;其中2025年第三季度,公司单季度主营收入8478.18万元,同比上升164.39%;单季度归母净利润1594.31万元,同比上升176.31%;单季度扣非净利润1514.96万元,同比上升168.35%;负债率49.32%,投资收益7.06万元,财务费用716.6万元,毛利率56.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693"],"gpt_icon":0},{"id":"2579998038","title":"股市必读:*ST双成(002693)10月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579998038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579998038?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:19","pubTimestamp":1761675584,"startTime":"0","endTime":"0","summary":"董秘最新回复投资者: 贵公司3季度业绩数据是否能够做到真实有效?董秘: 尊敬的投资者您好,公司第五届董事会的任期为2025年1月9日至2026年1月9日。董秘: 尊敬的投资者您好,公司三季报的预约披露时间为2025年10月30日,具体业绩情况请以公司届时披露的定期报告为准,感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900002783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002693","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768444586564,"stockEarnings":[{"period":"1week","weight":0.0205},{"period":"1month","weight":0.1136},{"period":"3month","weight":-0.0027},{"period":"6month","weight":-0.0325},{"period":"1year","weight":-0.5504},{"period":"ytd","weight":0.0704}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海南双成药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"44166人(较上一季度减少19.43%)","perCapita":"9305股","listingDate":"2012-08-08","address":"海南省海口市秀英区兴国路16号","registeredCapital":"41468万元","survey":" 海南双成药业股份有限公司的主营业务是药品注射剂、固体制剂、原料药的研发、生产、销售。公司的主要产品是注射用生长抑素、注射用比伐芦定、依替巴肽注射液、醋酸奥曲肽注射液、注射用紫杉醇(白蛋白结合型)。公司曾荣获国家知识产权示范企业、优势企业奖励。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"*ST双成(002693)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供*ST双成(002693)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"*ST双成,002693,*ST双成股票,*ST双成股票老虎,*ST双成股票老虎国际,*ST双成行情,*ST双成股票行情,*ST双成股价,*ST双成股市,*ST双成股票价格,*ST双成股票交易,*ST双成股票购买,*ST双成股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"*ST双成(002693)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供*ST双成(002693)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}